Welcome to our dedicated page for Cardiff Oncology news (Ticker: CRDF), a resource for investors and traders seeking the latest updates and insights on Cardiff Oncology stock.
Cardiff Oncology, Inc. develops clinical-stage cancer therapies centered on PLK1 inhibition and its lead oral inhibitor onvansertib. Company news commonly covers onvansertib in RAS-mutated metastatic colorectal cancer, including the CRDF-004 Phase 2 program evaluating combinations with standard-of-care regimens such as FOLFIRI/bevacizumab and FOLFOX/bevacizumab.
Updates also include preclinical and investigator-initiated work in other oncology settings, including metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, triple-negative breast cancer, HER2-low breast cancer models and chronic myelomonocytic leukemia. Corporate releases also address oncology conference presentations, key opinion leader events, executive appointments, investor conferences and Nasdaq inducement equity grants.
Cardiff Oncology (Nasdaq: CRDF) will present new preclinical data on its oral PLK1 inhibitor onvansertib at the AACR Annual Meeting 2026 in San Diego.
The poster (Abstract 329) shows onvansertib enhanced antitumor activity and reversed resistance to trastuzumab deruxtecan (T-DXd) in therapy-resistant HER2-low breast cancer models. Presentation: April 19, 2026, 2:00 PM–5:00 PM PT. The poster will be posted to the company’s Scientific Publications page after the session.
Cardiff Oncology (Nasdaq: CRDF) announced that management will participate in three investor conferences in March 2026: TD Cowen on 03/04/26, Barclays on 03/10/26 and Leerink Partners on 03/11/26. Interested parties can view live webcasts and replays via the company’s Events page.
Cardiff Oncology (Nasdaq: CRDF) reported positive Phase 2 CRDF-004 results in first-line RAS-mutated metastatic colorectal cancer and provided full-year 2025 financials and a business update.
The 30 mg onvansertib + FOLFIRI/bev arm achieved a confirmed ORR of 72.2% versus 43.2% for combined SoC, and showed improved PFS (HR: 0.37, p<0.05). The company held $58.3M cash, expecting runway into Q1 2027, and named an interim CEO while searching for permanent CEO and CFO.
Cardiff Oncology (Nasdaq: CRDF) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference in a virtual format on February 25-26, 2026.
Interim CEO Mani Mohindru, PhD will present on 02/25/2026 at 1:20 PM ET. Management will hold 1x1 investor meetings. According to the company, a live webcast and replay will be available via the Events section of the Cardiff Oncology website.
Cardiff Oncology (NASDAQ: CRDF) reported positive Phase 2 CRDF-004 results for onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC). In an intent-to-treat analysis (data cut Jan 22, 2026) the 30 mg onvansertib + FOLFIRI/bevacizumab arm showed a confirmed objective response rate of 72.2% versus 43.2% for pooled standard of care, and a PFS hazard ratio 0.37 vs SoC (p=0.048) with median PFS not reached versus 10.97 months for SoC. Safety was manageable with no major additive toxicity. The company selected the 30 mg dose for a planned registrational program and expects final data and registrational plans in H1 2026.
Cardiff Oncology (Nasdaq: CRDF) announced executive leadership changes effective January 27, 2026, as it transitions toward late-stage clinical development. Mani Mohindru, PhD, a board member since 2021, was appointed interim CEO effective immediately. Mark Erlander, PhD, and James Levine stepped down as CEO and CFO. Brigitte Lindsay was promoted to Chief Accounting Officer after 14+ years with the company. The company has initiated searches for permanent CEO and CFO roles. Cardiff’s lead candidate, onvansertib, is in mid-stage development for RAS-mutated metastatic colorectal cancer and is being evaluated in multiple investigator-initiated studies across other tumor types.
Cardiff Oncology (Nasdaq: CRDF) announced clinical data from an investigator-sponsored Phase 1 poster on onvansertib in chronic myelomonocytic leukemia (CMML) to be presented at ASH 2025.
In a dose-escalation trial (N=9), onvansertib monotherapy was reported as relatively well-tolerated and showed preliminary efficacy in approximately 40% of patients, with one patient achieving an optimal marrow response at the 9 mg/m2 dose. The company is not currently planning to develop onvansertib for CMML.
Poster details: Dec 8, 2025, 6:00-8:00 PM EST; Speaker: Mrinal Patnaik, MD; Session 637, Poster III.
Cardiff Oncology (Nasdaq: CRDF) will present at Sidoti’s Year-End Virtual Investor Conference on December 11, 2025 at 4:00 PM ET. CEO Mark Erlander, PhD will deliver the presentation and host one-on-one meetings during the conference running December 10–11, 2025. Interested parties can register and access the live webcast via the company’s Events section. A webcast replay will be available after the presentation.
Cardiff Oncology (Nasdaq: CRDF) will present at the Piper Sandler 37th Annual Healthcare Conference, held December 2–4, 2025. Company management will participate in a fireside chat and 1x1 investor meetings.
Presenter: Mark Erlander, PhD, CEO. Presentation date/time: December 2, 2025 at 9:30 AM ET. Interested parties can register and watch a live webcast via the company’s Events page, and a replay will be available after the presentation.
Cardiff Oncology (Nasdaq: CRDF) reported Q3 2025 results and a business update on Nov 6, 2025. The company announced positive Phase 2 CRDF-004 data for onvansertib plus standard of care in first-line RAS-mutated metastatic colorectal cancer, citing a 19% improvement in confirmed ORR for the 30mg cohort at the July 8, 2025 data cut-off and early PFS separation favoring 30mg.
Cardiff reported $60.6 million in cash and investments as of Sept 30, 2025, net cash used in operating activities of $10.8 million in Q3 2025, and projects runway into Q1 2027. A clinical update is expected in Q1 2026.